DMAC
Income statement / Annual
Last year (2023), DiaMedica Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, DiaMedica Therapeutics Inc.'s net income was -$19.38 M.
See DiaMedica Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$500,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$30,000.00 |
$25,000.00 |
$24,000.00 |
$21,000.00 |
$21,000.00 |
$0.00 |
$4,000.00 |
$2,211.00 |
$4,459.99 |
$0.00 |
| Gross Profit |
-$30,000.00 |
-$25,000.00 |
-$24,000.00 |
-$21,000.00 |
-$21,000.00 |
$500,000.00 |
-$4,000.00 |
-$2,211.00 |
-$4,459.99 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$13.11 M
|
$7.84 M
|
$8.77 M
|
$8.31 M
|
$7.90 M
|
$4.52 M
|
$3.21 M
|
$1.76 M
|
$886,073.00
|
$3.71 M
|
| General & Administrative
Expenses |
$8.16 M
|
$6.16 M
|
$4.88 M
|
$4.39 M
|
$3.69 M
|
$2.74 M
|
$1.31 M
|
$718,045.00
|
$423,354.00
|
$1.12 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.16 M
|
$6.16 M
|
$4.88 M
|
$4.39 M
|
$3.69 M
|
$2.74 M
|
$1.31 M
|
$718,045.00
|
$423,354.00
|
$1.12 M
|
| Other Expenses |
$0.00 |
$353,000.00 |
$82,000.00 |
-$205,000.00 |
-$856,000.00 |
-$68,000.00 |
$6,000.00 |
$221,902.00 |
$3,002.83 |
$0.00 |
| Operating Expenses |
$21.27 M |
$14.00 M |
$13.65 M |
$12.49 M |
$10.74 M |
$6.05 M |
$4.28 M |
$2.48 M |
$1.31 M |
$4.83 M |
| Cost And Expenses |
$21.27 M |
$14.00 M |
$13.65 M |
$12.49 M |
$10.74 M |
$6.05 M |
$4.28 M |
$2.48 M |
$1.31 M |
$4.83 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1,729.00 |
$1,739.58 |
$10,536.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$48,375.00 |
$43,955.00 |
$0.00 |
| Depreciation &
Amortization |
$30,000.00
|
$25,000.00
|
$24,000.00
|
$21,000.00
|
$21,000.00
|
$15,000.00
|
$4,000.00
|
$2,211.00
|
$4,111.87
|
$2,468.00
|
| EBITDA |
-$19.31 M
|
-$13.98 M
|
-$13.62 M
|
-$12.24 M
|
-$10.60 M
|
-$5.64 M
|
-$4.26 M
|
-$2.15 M
|
-$1.50 M
|
-$5.01 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
-10.99 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
-13.52
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.93 M
|
$353,000.00
|
$82,000.00
|
$434,000.00
|
$975,000.00
|
$747,000.00
|
$259,000.00
|
$280,630.00
|
-$104,384.00
|
-$185,410.29
|
| Income Before Tax |
-$19.34 M |
-$13.65 M |
-$13.56 M |
-$12.27 M |
-$10.62 M |
-$5.65 M |
-$4.26 M |
-$2.20 M |
-$1.43 M |
-$4.78 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
-11.31
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$43,000.00 |
$28,000.00 |
$28,000.00 |
$27,000.00 |
$31,000.00 |
$80,000.00 |
-$9,000.00 |
$22,314.00 |
$12,450.00 |
$42,284.00 |
| Net Income |
-$19.38 M |
-$13.68 M |
-$13.59 M |
-$12.29 M |
-$10.65 M |
-$5.73 M |
-$4.26 M |
-$2.22 M |
-$1.44 M |
-$4.82 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
-11.47 |
0 |
0 |
0 |
0 |
| EPS |
-0.6 |
-0.52 |
-0.65 |
-0.78 |
-0.89 |
-0.74 |
-0.72 |
-0.47 |
-0.4 |
-1.55 |
| EPS Diluted |
-0.6 |
-0.52 |
-0.65 |
-0.78 |
-0.89 |
-0.74 |
-0.72 |
-0.47 |
-0.4 |
-1.55 |
| Weighted Average Shares
Out |
$32.57 M
|
$26.44 M
|
$20.77 M
|
$15.68 M
|
$11.99 M
|
$7.74 M
|
$5.94 M
|
$4.74 M
|
$3.62 M
|
$3.11 M
|
| Weighted Average Shares
Out Diluted |
$32.57 M
|
$26.44 M
|
$20.77 M
|
$15.68 M
|
$11.99 M
|
$7.74 M
|
$5.94 M
|
$4.74 M
|
$3.62 M
|
$3.11 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
